Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

436.12 -11.43 (-2.55%)

Streaming Delayed Price Updated: 11:57 AM EDT, Jun 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

74 75 Next >

2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗

April 19, 2026

Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases.

Via The Motley Fool

Is Vertex Pharmaceuticals' Empire in Trouble? ↗

April 16, 2026

It might not be too late to invest in this company.

Via The Motley Fool

1 S&P 500 Stock on Our Watchlist and 2 Facing Challenges

April 16, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

Via StockStory

Topics Stocks

Trump's Team Says Don't Worry About Rising Inflation. Here Are 3 Stocks to Buy If They're Wrong. ↗

April 14, 2026

Could the White House be overly optimistic about inflation? If so, you may want to own these stocks.

Via The Motley Fool

Topics Economy Government

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Growth and Technical Setup ↗

April 03, 2026

Via Chartmill

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment ↗

March 28, 2026

Via Chartmill

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Merges Strong Fundamentals with Bullish Technical Setup ↗

March 13, 2026

Via Chartmill

Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position? ↗

April 07, 2026

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor.

Via The Motley Fool

Topics ETFs

Vertex to Announce First Quarter 2026 Financial Results on May 4th

April 06, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

April 02, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou...

Via StockStory

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

April 01, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500...

Via MarketMinute

Topics Economy Intellectual Property Stocks

1 Cash-Producing Stock with Promising Prospects and 2 We Turn Down

March 30, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Prediction: The Trump Bull Market Is About to End -- but These Stocks Will Rise Anyway ↗

March 28, 2026

Some stocks can zig when the overall market zags.

Via The Motley Fool

Topics Economy Energy Government

2 Stocks I Plan to Hold for the Next 20 Years ↗

March 27, 2026

These companies help me sleep peacefully at night.

Via The Motley Fool

Topics Intellectual Property

2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds

March 27, 2026

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

Via StockStory

Where Will Vertex Pharmaceuticals Be in 1 Year? ↗

March 25, 2026

The biotech's recent dip might be a buying opportunity.

Via The Motley Fool

CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? ↗

March 23, 2026

The gene-editing stock has been in a tailspin of late.

Via The Motley Fool

New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST

March 21, 2026

Via ACCESS Newswire

Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026

March 20, 2026

As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant...

Via Finterra

Topics Intellectual Property

Is CRISPR Therapeutics Stock a Buy Now? ↗

March 20, 2026

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Via The Motley Fool

My Top 3 Drug Stocks for March 2026 ↗

March 20, 2026

These companies have impressive track records of navigating the biggest challenges in their industry.

Via The Motley Fool

Topics Intellectual Property

Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals ↗

March 19, 2026

Both have plenty to offer investors, but one has a better outlook.

Via The Motley Fool

Topics Artificial Intelligence

Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks

March 17, 2026

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD...

Via StockStory

Topics Artificial Intelligence

1 Momentum Stock to Research Further and 2 We Ignore

March 16, 2026

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...

Via StockStory

Is Vertex Pharmaceuticals Heading to $600? ↗

March 15, 2026

A new product approval may be right around the corner.

Via The Motley Fool

This Stock Just Jumped By 8%: Is It Too Late to Buy? ↗

March 13, 2026

The drugmaker is getting its mojo back.

Via The Motley Fool

2 Reasons to Watch VRTX and 1 to Stay Cautious

March 13, 2026

Vertex Pharmaceuticals’s 22.2% return over the past six months has outpaced the S&P 500 by 19.8%, and its stock price has climbed to $480.31 per share. This ...

Via StockStory

Topics Stocks

Vertex Pharmaceuticals Surges 8.3% as Renal Breakthrough Sparks Market Rally

March 11, 2026

In a significant milestone for precision medicine, Vertex Pharmaceuticals (NASDAQ:VRTX) emerged as the top performer in the S&P 500 on March 11, 2026, with its shares climbing 8.3%. The rally followed...

Via MarketMinute

Topics Stocks

Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc

March 11, 2026

Check out the companies making headlines yesterday: nLIGHT (NASDAQ:LASR): Laser company nLIGHT (NASDAQ:LASR) rose by 5.5% on Tuesday after the market reacted...

Via StockStory

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.